Thomas Decker

16.1k total citations · 2 hit papers
254 papers, 7.3k citations indexed

About

Thomas Decker is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Thomas Decker has authored 254 papers receiving a total of 7.3k indexed citations (citations by other indexed papers that have themselves been cited), including 151 papers in Oncology, 109 papers in Pulmonary and Respiratory Medicine and 80 papers in Cancer Research. Recurrent topics in Thomas Decker's work include Colorectal Cancer Treatments and Studies (67 papers), Advanced Breast Cancer Therapies (57 papers) and Breast Cancer Treatment Studies (57 papers). Thomas Decker is often cited by papers focused on Colorectal Cancer Treatments and Studies (67 papers), Advanced Breast Cancer Therapies (57 papers) and Breast Cancer Treatment Studies (57 papers). Thomas Decker collaborates with scholars based in Germany, Austria and United States. Thomas Decker's co-authors include Christian Peschel, Folker Schneller, Ingo Ringshausen, Christian Bogner, Susanne Hipp, Madlene Oelsner, Werner Boecker, Emad A. Rakha, Ian O. Ellis and Stuart J. Schnitt and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Blood.

In The Last Decade

Thomas Decker

238 papers receiving 7.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Breast cancer prognostic classification in the molecular era: the role of histological grade

2010 648 citations Thomas Decker et al. profile →
Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists

2010 506 citations Thomas Decker et al. profile →

Peers

Countries citing papers authored by Thomas Decker

Since Specialization

Citations

This map shows the geographic impact of Thomas Decker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Decker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Decker more than expected).

Fields of papers citing papers by Thomas Decker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Decker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Decker. The network helps show where Thomas Decker may publish in the future.

Co-authorship network of co-authors of Thomas Decker

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Decker. A scholar is included among the top collaborators of Thomas Decker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Decker. Thomas Decker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Influence of hydrodynamic planetary journal bearings on the NVH-behavior of wind turbines 2025 ·Forschung im Ingenieurwesen ·(unknown), Georg Jacobs, Thomas Decker, (unknown), Ralf Schelenz	1
2	Consensus molecular subtypes (CMS) as prognostic and predictive biomarkers of RAS wild-type (WT) metastatic colorectal cancer (mCRC): Pooled analysis of the randomized trials FIRE-1, FIRE-3, XELAVIRI, and PanaMa. 2024 ·Journal of Clinical Oncology ·Arndt Stahler, Dominik Paul Modest, Sebastian Stintzing, Swantje Held, Ludwig Fischer von Weikersthal, Lothar Müller, Ullrich Graeven, Thomas Decker, Tobias Heintges, Christoph Kahl, Werner Scheithauer, Alexander Kiani, Florian Kaiser, Ingo Schwaner, (unknown), (unknown), (unknown), (unknown), David Horst, Volker Heinemann	0
3	Head‐to‐head comparison of palbociclib and ribociclib in first‐line treatment of HR‐positive/HER2‐negative metastatic breast cancer with real‐world data from the OPAL registry 2024 ·International Journal of Cancer ·Marc Thill, (unknown), Anja Welt, Arnd Nusch, Matthias Zaiß, (unknown), (unknown), Kai G. Ringwald, (unknown), (unknown), (unknown), Martina Jänicke, H. Schulz, Volker Hagen, (unknown), Elmar Stickeler, Nadia Harbeck, Achim Wöckel, Thomas Decker	5
4	Refining first-line treatment decision in RAS wildtype (RAS-WT) metastatic colorectal cancer (mCRC) by combining clinical biomarkers: Results of the randomized phase 3 trial FIRE-3 (AIO KRK0306). 2024 ·Journal of Clinical Oncology ·Julian Walter Holch, (unknown), Sebastian Stintzing, Kathrin Heinrich, (unknown), (unknown), (unknown), Thomas Decker, Alexander Kiani, Florian Kaiser, Tobias Heintges, Christoph Kahl, Frank Kullmann, Werner Scheithauer, Hartmut Link, Heinz‐Gert Hoeffkes, Markus Moehler, Dominik Paul Modest, Michael P. Menden, Volker Heinemann	1
5	Favorable impact of therapy management by an interactive eHealth system on severe adverse events in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapy 2023 ·Cancer Treatment Reviews ·Nadia Harbeck, Ronald Kates, Timo Schinköthe, (unknown), Rachel Wuerstlein, Tom Degenhardt, Diana Lüftner, (unknown), Oliver Hoffmann, Ralf Lorenz, Thomas Decker, Mattea Reinisch, Thomas Göhler, Peter Staib, Oleg Gluz, Peter A. Fasching, Marcus Schmidt	6
6	Cell-free circulating RAS mutation concentrations significantly impact the survival of metastatic colorectal cancer patients 2023 ·Journal of Cancer Research and Clinical Oncology ·Axel Muendlein, Kathrin Geiger, Christine Heinzle, (unknown), Thomas Winder, (unknown), (unknown), Eva Maria Brandtner, Andreas Leiherer, Heinz Drexel, Thomas Decker, (unknown), Tobias Dechow	5
7	Circulating Glypican-4 Is a Predictor of 24-Month Overall Survival in Metastatic Breast Cancer 2023 ·Oncology Research and Treatment ·Axel Muendlein, Christine Heinzle, Eva Maria Brandtner, Andreas Leiherer, Heinz Drexel, Tobias Dechow, Thomas Decker	5
8	441P Real-world efficacy of ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL) in subgroups of special interest: 5th interim analysis (IA) of the RIBANNA study 2023 ·Annals of Oncology ·(unknown), Cosima Brucker, Thomas Decker, PA Fasching, Thomas Göhler, Christian Jackisch, Jan Janßen, Astrid Koehler, Kerstin Lüedtke-Heckenkamp, Diana Lüftner, (unknown), Frederik Marmé, (unknown), Beate Rautenberg, Toralf Reimer, Rudolf Weide, Pauline Wimberger, (unknown), (unknown), Marjanka K. Schmidt	1
9	First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer – Final survival and per-protocol analysis of the randomised XELAVIRI trial (AIO KRK 0110) 2022 ·European Journal of Cancer ·Arndt Stahler, Dominik Paul Modest, Ludwig Fischer von Weikersthal, Florian Kaiser, Thomas Decker, Swantje Held, Ullrich Graeven, Ingo Schwaner, Claudio Denzlinger, Michael Schenk, Annika Kurreck, Kathrin Heinrich, Clemens Gießen-Jung, Jens Neumann, Thomas Kirchner, Andreas Jung, Sebastian Stintzing, Volker Heinemann	1
10	Clonal Evolution in Patients with Hormone Receptor Positive, HER-2 Negative Breast Cancer Treated with Chemotherapy or CDK4/6 Inhibitors 2022 ·Oncology Research and Treatment ·Thomas Decker, (unknown), (unknown), Gerhard W. Fischer, Kathrin Geiger, (unknown), (unknown), Tobias Dechow, Axel Muendlein	3
11	Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial) 2021 ·European Journal of Cancer ·Arndt Stahler, Volker Heinemann, (unknown), Kathrin Heinrich, Annika Kurreck, Clemens Gießen-Jung, Ludwig Fischer von Weikersthal, Florian Kaiser, Thomas Decker, Swantje Held, Ullrich Graeven, Ingo Schwaner, Claudio Denzlinger, Michael Schenk, Jens Neumann, Thomas Kirchner, Andreas Jung, Jörg Kumbrink, Sebastian Stintzing, Dominik Paul Modest	4
12	Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer—findings from the RIBECCA trial 2021 ·European Journal of Cancer ·(unknown), (unknown), (unknown), (unknown), Enio Gjerga, Steffen Hennig, Sigrid Schaper, Il‐Kang Na, Ulrich Keller, Sara Y. Brucker, Thomas Decker, Peter A. Fasching, Tanja Fehm, Wolfgang Janni, Sherko Kümmel, Andreas Schneeweiß, Martin Schüler, Diana Lüftner, Antonia Busse	19
13	Improving Chemotherapy-Induced Peripheral Neuropathy in Patients with Breast or Colon Cancer after End of (Neo)adjuvant Therapy: Results from the Observational Study STEFANO 2021 ·Oncology Research and Treatment ·Matthias Zaiß, Jens Uhlig, (unknown), Thomas Decker, Helmar C. Lehmann, (unknown), (unknown), Corinne Vannier, Norbert Marschner	6
14	Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials 2020 ·Clinical Cancer Research ·Arndt Stahler, Sebastian Stintzing, Dominik Paul Modest, Ingrid Ricard, Clemens Gießen-Jung, (unknown), (unknown), Florian Kaiser, Ludwig Fischer von Weikersthal, Nicolas Moosmann, Andreas Schalhorn, Martina Stauch, Alexander Kiani, Swantje Held, Thomas Decker, Markus Moehler, Jens Neumann, Thomas Kirchner, Andreas Jung, Volker Heinemann	20
15	Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer 2020 ·BMC Cancer ·Thomas Decker, Ulrike Söling, Antje Hahn, Christoph Maintz, Christian M. Kurbacher, Ursula Vehling‐Kaiser, (unknown), Peter Klare, Volker Hagen, Marco Chiabudini, (unknown), (unknown), Eva Diana Runkel, Karin Potthoff	4
16	Impact of age on efficacy and early mortality of initial sequential treatment versus upfront combination chemotherapy in patients with metastatic colorectal cancer: a subgroup analysis of a phase III trial (AIO KRK0110, XELAVIRI study) 2020 ·European Journal of Cancer ·Annika Kurreck, Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, Florian Kaiser, Jens Uhlig, Michael Schenk, Jens Freiberg‐Richter, (unknown), Claudio Denzlinger, Ullrich Graeven, Ingo Schwaner, Arndt Stahler, Kathrin Heinrich, Andreas Jung, Swantje Held, Jobst C. von Einem, Sebastian Stintzing, Clemens Gießen-Jung, Dominik Paul Modest	6
17	St Gallen 2015 subtyping of luminal breast cancers: impact of different Ki67-based proliferation assessment methods 2016 ·Breast Cancer Research and Treatment ·Cornelia M. Focke, P. J. van Diest, Thomas Decker	36
18	[Sentinel node biopsy in breast cancer]. 2004 ·PubMed ·Thorsten Kühn, A. Bembenek, (unknown), Thomas Decker, Juergen Dunst, U. Müllerleile, D. L. Munz, H. Ostertag, M.-L. Sautter-Bihl, Holger Schirrmeister, A. H. Tulusan, Michael Untch, Klaus‐Jürgen Winzer, Christian Wittekind	2
19	Standardisierte pathologische Untersuchung von Mamma-Exzisionspräparaten Relevanz innerhalb eines interdisziplinären Praxisprotokolls für das Qualitätsmanagement der brusterhaltenden Therapie 1997 ·Der Pathologe ·Thomas Decker, Markus Ruhnke, W Schneider	1
20	Duktale Hyperplasie und Duktales Carcinoma in situ Definition – Klassifikation – Differentialdiagnose 1997 ·Der Pathologe ·W. Böcker, Thomas Decker, Markus Ruhnke, W. Schneider	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact